These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 32036861)

  • 21. A review of current key guidelines for managing high-risk patients with diabetes and heart failure and future prospects.
    Lee MMY; Sattar N
    Diabetes Obes Metab; 2023 Jul; 25 Suppl 3():33-47. PubMed ID: 37041663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Impact of Patients With Cardiac Amyloidosis in HFpEF Trials.
    Oghina S; Bougouin W; Bézard M; Kharoubi M; Komajda M; Cohen-Solal A; Mebazaa A; Damy T; Bodez D
    JACC Heart Fail; 2021 Mar; 9(3):169-178. PubMed ID: 33549560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial).
    Jariwala P; Jadhav K; Punjani A; Boorugu H; Mari AR
    Indian Heart J; 2021; 73(5):605-611. PubMed ID: 34627577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure.
    Prenner SB; Shah SJ; Yancy CW
    Curr Atheroscler Rep; 2016 Aug; 18(8):48. PubMed ID: 27324636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of pharmacological treatment on outcomes of heart failure with preserved ejection fraction: an updated systematic review and network meta-analysis of randomized controlled trials.
    Lin Y; Cai Z; Yuan J; Liu H; Pang X; Chen Q; Tang X; Geng Q; Dong S
    Cardiovasc Diabetol; 2022 Nov; 21(1):237. PubMed ID: 36348348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction.
    McDonald M; Virani S; Chan M; Ducharme A; Ezekowitz JA; Giannetti N; Heckman GA; Howlett JG; Koshman SL; Lepage S; Mielniczuk L; Moe GW; O'Meara E; Swiggum E; Toma M; Zieroth S; Anderson K; Bray SA; Clarke B; Cohen-Solal A; D'Astous M; Davis M; De S; Grant ADM; Grzeslo A; Heshka J; Keen S; Kouz S; Lee D; Masoudi FA; McKelvie R; Parent MC; Poon S; Rajda M; Sharma A; Siatecki K; Storm K; Sussex B; Van Spall H; Yip AMC
    Can J Cardiol; 2021 Apr; 37(4):531-546. PubMed ID: 33827756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction.
    Jhund PS
    Heart Fail Clin; 2022 Oct; 18(4):579-586. PubMed ID: 36216487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. When and How to Use Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction or Chronic Kidney Disease.
    O'Meara E; Verma S
    Can J Cardiol; 2021 Apr; 37(4):669-673. PubMed ID: 33450364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The PARAGON-HF trial].
    Tridetti J; Nguyen Trung ML; Ancion A; Lancellotti P
    Rev Med Liege; 2020 Feb; 75(2):130-135. PubMed ID: 32030940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodium-glucose co-transporter 2 inhibitors?
    Berezin AE; Berezin AA
    Future Cardiol; 2021 May; 17(3):497-506. PubMed ID: 33615880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines.
    Tsutsui H
    Pharmacol Ther; 2022 Oct; 238():108185. PubMed ID: 35413307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can HFpEF and HFrEF Coexist?
    Schiattarella GG; Tong D; Hill JA
    Circulation; 2020 Mar; 141(9):709-711. PubMed ID: 32119583
    [No Abstract]   [Full Text] [Related]  

  • 33. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
    Nakagawa Y; Kuwahara K
    J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The year in cardiovascular medicine 2021: heart failure and cardiomyopathies.
    Bauersachs J; de Boer RA; Lindenfeld J; Bozkurt B
    Eur Heart J; 2022 Feb; 43(5):367-376. PubMed ID: 34974611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study.
    Hsiao FC; Lin CP; Tung YC; Chang PC; McMurray JJV; Chu PH
    Int J Cardiol; 2021 May; 330():91-97. PubMed ID: 33587940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions.
    Ambrosy AP; Mentz RJ; Fiuzat M; Cleland JGF; Greene SJ; O'Connor CM; Teerlink JR; Zannad F; Solomon SD
    Eur J Heart Fail; 2018 Jun; 20(6):963-972. PubMed ID: 29464817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of Heart Failure With Preserved Ejection Fraction in Elderly Patients: Effectiveness and Safety.
    Elkammash A; Tam SSC; Yogarajah G; You J
    Cureus; 2023 Feb; 15(2):e35030. PubMed ID: 36938226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future.
    Wintrich J; Kindermann I; Ukena C; Selejan S; Werner C; Maack C; Laufs U; Tschöpe C; Anker SD; Lam CSP; Voors AA; Böhm M
    Clin Res Cardiol; 2020 Sep; 109(9):1079-1098. PubMed ID: 32236720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A Breakthrough in the Treatment of Patients With Heart Failure With Reduced Ejection Fraction: the Clinical Significance of the PARADIGM HF-Trial].
    Kobalava ZD; Villevalde SV; Lukina OI
    Kardiologiia; 2017 Feb; 57(2):76-82. PubMed ID: 28290795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of Heart Failure With Reduced Ejection Fraction in Patients With Diabetes Mellitus and Chronic Kidney Disease.
    Khan MS; Rashid AM; Shafi T; Ferreira JP; Butler J
    Semin Nephrol; 2023 May; 43(3):151429. PubMed ID: 37871362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.